Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

20071,260 citationsReview

Authors

Abstract

Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes. Serious heart failure is increased by pioglitazone, although without an associated increase in mortality.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Peroxisome Proliferator-Activated Receptors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 298, Issue 10, pp. 1180-8

DOI: 10.1001/jama.298.10.1180

Field-Weighted Citation Impact: 80.44